3/6/2017 12:00:00 AM | less than a minute read

Immuno-oncology: great risks and greater rewards

Get in touch

Bruce Rychlik

Managing Partner, Life Sciences

Get in touch

Bruce Rychlik

Managing Partner, Life Sciences

The headline-grabbing field of immuno-oncology holds promises and challenges. Informative yet general articles (like this) reinforce what those who have spent decades in and around the industry have come to expect:

Significant capital
Intense competition
Lengthy approval timelines
High sales expectation
Higher company valuations
Need for patient stratification
And, most importantly, the possibility for profound impact on human health

But the current immunotherapies don’t benefit all patients—a limitation spurring the industry to hunt for new ways to push immune cells to destroy tumors. Companies big and small are racing to develop these new medicines, which analysts say could help boost global cancer immunotherapy sales to more than $40 billion a year by the middle of the next decade, from more than $6 billion in 2016.

www.wsj.com/...